Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31249603 | 0.91 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25298079 | 0.91 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25250910 | 0.91 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14666763 | 0.83 | ADH1B (0.38) | — | |
| SCHEMBL28410256 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6125628 | 0.78 | GPR119 (0.34) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL135183 | 0.78 | HSD11B1 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14659524 | 0.77 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL14659525 | 0.77 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL4913906 | 0.77 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957229-A | Tyrosine kinase inhibitors | 爱丁堡大学理事会 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023017264-A1 | TYROSINE KINASE INHIBITORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2013026587-A1 | 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |
| CN-101300226-B | Alkylcarbamoyl naphthoxyoctenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and process for preparing the same | KOREA RES INST CHEM TECH | 2012-05-30 | — | — | CN | disclosed |
| WO-2012066077-A1 | 1,4 DI SUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| US-8030502-B2 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| CN-101300226-A | Alkylcarbamoyl naphthoxyoctenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and process for preparing the same | KOREA RES INST CHEM TECH (KR) | 2008-11-05 | — | — | CN | disclosed |
| US-20080091034-A1 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | THERAVANCE, INC. | 2008-04-17 | — | — | US | disclosed |
| CN-100364990-C | Substituted 4-amino-1- (pyridylmethyl) piperidines and related compounds | THERAVANCE INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-7285564-B2 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | THERAVANCE, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1556372-B1 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2007-05-30 | — | — | EP | disclosed |
| CN-1875017-A | Naphthalene-1, 5-disulfonic acid salts of substituted 4-amino-1- (pyridylmethyl) piperidine compounds | THERAVANCE INC (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1680416-A2 | NAPHTHALENE-1,5-DISULFONIC ACID SALTS OF A SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE COMPOUND | Theravance, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| CN-1708494-A | Substituted 4-amino-1- (pyridylmethyl) piperidines and related compounds | THERAVANCE INC (US) | 2005-12-14 | — | — | CN | disclosed |
| EP-1556372-A2 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050113413-A1 | Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound | THERAVANCE, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005042514-A2 | NAPHTHALENE-1,5-DISULFONIC ACID SALTS OF A SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE COMPOUND | THERAVANCE, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004041806-A2 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113413-A1 | Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound | CHRM1, NPSR1, CHRM3 | SLC6A2 492/4885SLC6A4 552/4885SLC6A3 289/4885 |
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | CHRM2, CHRM1, CHRM3 | SLC6A2 3624/4885SLC6A4 2326/4885SLC6A3 2775/4885 |
| US-20080091034-A1 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | CHRM5, CHRM1, CHRM3 | SLC6A2 2263/4885SLC6A4 909/4885SLC6A3 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.